ArticleLancet (London, England)2012
The 2011 EBCTCG polychemotherapy overview.
Article in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.International journal of nanomedicine · 2014Trial
- Establishment of a model to predict the recurrence time of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.Translational cancer research · 2026Article
- Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.ESMO open · 2020Article
- Review
- Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.Archives of gynecology and obstetrics · 2020Article
- Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.Oncology letters · 2019Article
- Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure.OncoTargets and therapy · 2019Article
- Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.Scientific reports · 2017Article
- Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.Breast cancer research : BCR · 2016Article
- Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.The oncologist · 2015Article
- In reply.The oncologist · 2015Article
- Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.F1000Research · 2014Review
- PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.OncoTargets and therapy · 2014Article
- The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?Current oncology reports · 2014Review
- Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013Article
- Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.CMAJ open · 2013Article
- Taxane benefit in breast cancer--a role for grade and chromosomal stability.Nature reviews. Clinical oncology · 2013Review
- Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.ISRN oncology · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22152852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.